Canaccord has recently increased its price target for Biodesix, a move attributed to more favorable revenue forecasts.
This adjustment suggests that analysts at Canaccord are optimistic about the company's financial performance moving forward.
Investors may want to keep an eye on Biodesix as it navigates these updated projections.